Omalizumab Reference: HY-P9950 Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research.
Palivizumab Reference: HY-P9944 Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
Sontuzumab Reference: HY-P99591 Sontuzumab (AS1402) is a humanised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer.
Briquilimab Reference: HY-P99488 Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID).
Enfortumab Reference: HY-P99016 Enfortumab is a monoclonal antibody targeting Nectin-4. Enfortumab can used for researching urothelial cancer.
Izuralimab Reference: HY-P99679 Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1.